LNFP III and LSTa Composition for Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory diseases such as psoriasis, ankylosing spondylitis, and RA often have limited efficacy and can lead to adverse effects due to systemic administration, and there is a need for compositions that can modulate the balance between regulatory T cells and Th17 cells to effectively manage inflammatory responses and autoimmune conditions.
Innovation Solution
A synthetic composition comprising lacto-N-fucopentaose III (LNFP III) and sialyllacto-N-tetraose a (LSTa) is developed, which regulates the expression of FoxP3 and IL10, thereby modulating immune responses and reducing inflammation, and can be used in both therapeutic and non-therapeutic treatments, including infant formulas.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic drug administration is used to treat inflammatory diseases, then therapeutic effect is achieved, but adverse events and limited efficacy occur
Solution Approach 1:
The invention segments the therapeutic approach by using specific oligosaccharide components (LNFP III and LSTa) that can selectively modulate immune responses in specific tissues, particularly the intestine, rather than systemic administration. This targeted segmentation reduces adverse events while maintaining therapeutic efficacy for inflammatory diseases.
Solution Approach 2:
The composition achieves local quality by concentrating immunomodulatory effects in specific tissues through the use of oligosaccharides that can accumulate in intestinal tissue. This local action provides therapeutic benefit while minimizing systemic adverse events associated with conventional drug administration.
2Reliability
If conventional therapies are used for inflammatory diseases, then treatment is provided, but the balance between regulatory T cells and Th17 cells is not effectively modulated
Solution Approach 1:
The invention changes the parameter of immune modulation by using oligosaccharides that specifically influence the Treg/Th17 balance through mechanisms distinct from conventional drugs. The composition alters cytokine profiles and cell differentiation parameters to achieve effective immune response modulation with improved adaptability.
Data Source
AI summary
A synthetic composition comprising a carbohydrate component, a fat component and a protein component, wherein the carbohydrate component comprises lacto-N-fucopentaose III (LNFP III) and sialyllacto-N-tetraose a (LSTa), preferably wherein the weight ratio between LNFP III and LSTa is between 1:100 and 100:1.